Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 07, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: GBP 14.514 per Ordinary Share.
- Transaction Type: Re-investment of dividends paid on October 06, 2005.
Material Changes
The filing details specific increases in shareholdings for the following individuals following the dividend re-investment:
- Mr R Bondy: 145 shares
- Mr J Heslop: 110 shares
- Mrs C Witty: 221 shares
- Mrs C Pulman: 11 shares
- Mr D Pulman: 58 shares
No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of director share transactions in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares held by the named directors prior to this transaction to assess total ownership concentration.
- Confirm the dividend amount per share to validate the re-investment calculation based on the GBP 14.514 price.
- Check subsequent filings for any further changes in director holdings or related party transactions.